Search
Akari Therapeutics PLC
AKTXAdd to Watchlist
7.800USD
-0.200-2.50%
Close 07-31 16:00（ET）Quotes delayed by 15 min
8.93MMarket Cap
LossP/E TTM
More Details of Akari Therapeutics PLC Company
Akari Therapeutics, Plc is a biotechnology company developing precision bifunctional antibody drug conjugates (ADC) for the treatment of cancer. Utilizing its ADC discovery platform, it generates bifunctional ADC candidates and optimizes them based on the desired application to target a range of cancers. Its lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells, and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. PH1 is a novel bifunctional payload that is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while generating immunostimulatory effects and minimizing off-target toxicity. Its pipeline includes AKTX-101 and AKTX-102, a discovery-stage ADC that pairs PH1 with an undisclosed target antibody. It is pursuing research on two additional novel payloads, such as PH5 and PH6. It also has an ADC Platform for oncology and PHP-303 program for genetic disease, liver disease and inflammation.
Akari Therapeutics PLC Info
Ticker SymbolAKTX
Company nameAkari Therapeutics PLC
IPO dateJan 31, 2014
CEOGaslightwala (Abizer)
Number of employees8
Security typeDepository Receipt
Fiscal year-endJan 31
Address401 East Jackson Street
CityTAMPA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33602
Phone19292747510
Websitehttps://www.akaritx.com/
Ticker SymbolAKTX
IPO dateJan 31, 2014
CEOGaslightwala (Abizer)
Company Executives of Akari Therapeutics PLC
Name
Name/Position
Position
Shareholding
Change
Mr. Hoyoung Huh, M.D., Ph.D.
Mr. Hoyoung Huh, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
117.40K
--
Mr. Kameel D. Farag
Mr. Kameel D. Farag
Interim Chief Financial Officer
Interim Chief Financial Officer
20.45K
+92.07%
Mr. Abizer Gaslightwala
Mr. Abizer Gaslightwala
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.57K
+7.99%
Mr. Robert B. (Rob) Bazemore, Jr.
Mr. Robert B. (Rob) Bazemore, Jr.
Independent Director
Independent Director
1.12K
--
Dr. Raymond (Ray) Prudo-chlebosz, M.D.
Dr. Raymond (Ray) Prudo-chlebosz, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Samir R. Patel, M.D.
Dr. Samir R. Patel, M.D.
Director
Director
--
--
Mr. James Neal
Mr. James Neal
Independent Director
Independent Director
--
--
Mr. Sandip I Patel, J.D.
Mr. Sandip I Patel, J.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Hoyoung Huh, M.D., Ph.D.
Mr. Hoyoung Huh, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
117.40K
--
Mr. Kameel D. Farag
Mr. Kameel D. Farag
Interim Chief Financial Officer
Interim Chief Financial Officer
20.45K
+92.07%
Mr. Abizer Gaslightwala
Mr. Abizer Gaslightwala
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.57K
+7.99%
Mr. Robert B. (Rob) Bazemore, Jr.
Mr. Robert B. (Rob) Bazemore, Jr.
Independent Director
Independent Director
1.12K
--
Dr. Raymond (Ray) Prudo-chlebosz, M.D.
Dr. Raymond (Ray) Prudo-chlebosz, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Samir R. Patel, M.D.
Dr. Samir R. Patel, M.D.
Director
Director
--
--
FAQs
Who are the top five shareholders of Akari Therapeutics PLC?
The top five shareholders of Akari Therapeutics PLC are: Mr. Hoyoung Huh, M.D., Ph.D.
How many institutions hold shares of Akari Therapeutics PLC (AKTX)?
As of 2026Q1, 34 institutions hold shares of Akari Therapeutics PLC, with a combined market value of approximately 98.01K, accounting for 8.56% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 51621.00.